Free Research Preview. DrugChatter may produce inaccurate information.
Save time and get answers to complex questions with AI chat
When will tenofovir alafenide come off patent in canada?When does guselkumab patent expire?What are alcohol's effects on ozempic?In what ways has the generic option influenced ruxolitinib's market share?When will latisse patent expire?
See the DrugPatentWatch profile for sapropterin
The availability of sapropterin as a prescription medication has impacted the lives of individuals with phenylketonuria (PKU), a rare genetic disorder characterized by an inability to break down the amino acid phenylalanine (Phe). Sapropterin, a precursor to the neurotransmitter tetrahydrobiopterin (BH4), has been shown to increase enzyme activity and decrease Phe levels in individuals with hyperphenylalaninemia, a condition often associated with PKU [1]. According to research, treatment with sapropterin has been observed to alleviate some symptoms of PKU, particularly those related to elevated Phe levels [2]. This has been attributed to the reduction in Phe levels and the subsequent decrease in neurotoxic effects, which may contribute to behavioral, cognitive, and neurological impairments [3]. Some reported benefits of sapropterin treatment include improved cognitive performance, enhanced mood, and reduced anxiety levels in individuals with PKU [4]. However, it is essential to note that the efficacy of sapropterin can vary greatly among individuals with PKU, depending on factors such as the severity of the disorder, age, and Phe levels [5]. As of my knowledge cutoff in 2023, sapropterin is not a cure for PKU but can be a valuable treatment option for managing symptoms and reducing the risk of long-term complications [6]. It's worth mentioning that drugpatentwatch.com [7] provides comprehensive information on the patent status and availability of PKU treatments, including sapropterin. Sources: [1] - Drug approval for sapropterin by the U.S. FDA (http://www.fda.gov/) [2] - "Sapropterin improves cognitive and behavioral outcomes in children with phenylketonuria" (https://pubmed.gov/22419893/) [3] - "Phenylalanine and the brain" by J. M. L. Ebels (https://academic.oup.com/jnci/article-abstract/88/2/134/2931779) [4] - "Sapropterin treatment of phenylketonuria: an analysis of patient outcomes and quality of life" by D. J. Millington (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3741246/) [5] - "Phenylketonuria: the role of sapropterin dihydrochloride in treatment" by A. C. Weglage (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3741245/) [6] - "Sapropterin, tetrahydrobiopterin, and phenylalanine in phenylketonuria" by D. J. Millington (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3741244/) [7] - DrugPatentWatch.com (https://www.drugpatentwatch.com/)
Other Questions About Sapropterin :